Holli Loomans-Kropp
Holli Loomans-Kropp, Ph.D., M.P.H.
Division of Cancer Prevention (DCP)
Entry Year
2017
Phone
240-276-7162

Doctoral Degree

Ph.D., Cancer Biology, Vanderbilt University (2017)

Master's Degree

M.P.H., University of Texas-Houston (2012)

Research Interests

Biomarkers; Early Detection; Epidemiology-Biology Bridge; Gastrointestinal Cancers; Translational Research

Primary Preceptor/Branch

Asad Umar, Gastrointestinal and Other Cancers Branch (GCB), Division of Cancer Prevention (DCP)

Program Spotlight

Dr. Loomans-Kropp, Dr. Pierre-Victor, with Division of Cancer Prevention Mentors, Publish on Personalized Risk

April 5, 2019

Current CPFP fellow Dr. Holli Loomans-Kropp, recently published a review in Precision Oncology titled “Cancer prevention and screening: the next step in the era of precision medicine.” In this piece, Loomans-Kropp and her Division of Cancer Prevention (DCP) preceptor and Chief of the Gastrointestinal and Other Cancers Research Group, Dr. Asad Umar, summarized the current state of cancer prevention efforts along the cancer control continuum. They discussed historical efforts in prevention, current prevention and early detection recommendations, and current knowledge of the molecular factors that may impact one’s risk of cancer. The review also explored the future of cancer prevention in the current age of precision medicine and personalized care.

Loomans-Kropp and Umar highlighted the necessity of combining generalized cancer prevention techniques with individualized methods. Loomans-Kropp noted, “Better understanding one’s personalized risk of one, or multiple, cancers may better inform how she or he should approach cancer prevention. This type of knowledge will allow for better and more precise guidance in cancer prevention.”

In February 2019, current CPFP fellow Dr. Dudith Pierre-Victor, with mentor and Chief of DCP’s Early Detection Research Branch Dr. Paul Pinsky, published a study in JAMA Internal Medicine. The study, titled “Association of Nonadherence to Cancer Screening Examinations with Mortality from Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial” examined the association between nonadherence to cancer screening tests and mortality in the Prostate, Lung, Colorectal Ovarian Cancer Screening Trial (PLCO), excluding mortality from cancer studied in the trial. Pierre-Victor and Pinsky observed higher mortality among participants who were nonadherent to baseline cancer screening tests compared to those who fully adhered. A general behavior profile of nonadherence, of which nonadherence specifically with trial protocol screening is a marker, was found to be associated with a very substantial increased risk of death.

Dr. Pierre-Victor stressed the impact of this study on middle-aged and older populations: “Study participants’ adherence profile is a behavioral characteristic that merits investigation since it is associated with an increased risk of mortality among middle-aged and older adults.”

Holli Loomans-Kropp, Ph.D., M.P.H.
Current Fellow, 2017 CPFP Cohort